Advanced search
Publication Cover
Leukemia & Lymphoma Volume 60, 2019 - Issue 4
Submit an article Journal homepage
443
Views
8
CrossRef citations to date
0
Altmetric
Letter to the Editor

Non-NAD-like PARP1 inhibitor enhanced synthetic lethal effect of NAD-like PARP inhibitors against BRCA1-deficient leukemia

Margaret Nieborowska-SkorskaDepartment of Microbiology and Immunology and Fels Institute for Cancer Research and Molecular Biology Lewis Katz School of Medicine, Temple University, Philadelphia, PA, USA; View further author information
,
Silvia MaifredeDepartment of Microbiology and Immunology and Fels Institute for Cancer Research and Molecular Biology Lewis Katz School of Medicine, Temple University, Philadelphia, PA, USA; View further author information
,
Min YeTemple University School of Pharmacy, Moulder Center for Drug Discovery Research, Philadelphia, PA, USA; View further author information
,
Monika TomaDepartment of Microbiology and Immunology and Fels Institute for Cancer Research and Molecular Biology Lewis Katz School of Medicine, Temple University, Philadelphia, PA, USA; ;Laboratory of Medical Genetics Faculty of Biology and Environmental Protection, University of Lodz, Lodz, Poland; View further author information
,
Elizabeth HewlettTemple University School of Pharmacy, Moulder Center for Drug Discovery Research, Philadelphia, PA, USA; View further author information
,
John GordonTemple University School of Pharmacy, Moulder Center for Drug Discovery Research, Philadelphia, PA, USA; View further author information
,
Bac Viet LeDepartment of Microbiology and Immunology and Fels Institute for Cancer Research and Molecular Biology Lewis Katz School of Medicine, Temple University, Philadelphia, PA, USA; ;Laboratory of Cytometry, Nencki Institute of Experimental Biology, Warsaw, Poland; View further author information
,
Tomasz SliwinskiLaboratory of Medical Genetics Faculty of Biology and Environmental Protection, University of Lodz, Lodz, Poland; View further author information
,
Huaqing ZhaoDepartment of Clinical Sciences Lewis Katz School of Medicine, Temple University, Philadelphia, PA, USA; View further author information
,
Katarzyna PiwockaLaboratory of Cytometry, Nencki Institute of Experimental Biology, Warsaw, Poland; View further author information
,
Peter ValentDepartment of Internal Medicine I Division of Hematology & Hemostaseology and Ludwig-Boltzmann Cluster Oncology, Medical University of Vienna, Austria, Vienna; View further author information
,
Alexei V. TulinDepartment of Biomedical Sciences School of Medicine and Health Sciences, University of North Dakota, Grand Forks, ND, USAView further author information
,
Wayne ChildersTemple University School of Pharmacy, Moulder Center for Drug Discovery Research, Philadelphia, PA, USA; View further author information
&
Tomasz SkorskiDepartment of Microbiology and Immunology and Fels Institute for Cancer Research and Molecular Biology Lewis Katz School of Medicine, Temple University, Philadelphia, PA, USA; Correspondence[email protected]
View further author information
 show all
Pages 1098-1101 | Received 06 Jun 2018, Accepted 01 Sep 2018, Published online: 02 Oct 2018

References

  • Bartkova J, Hořejší Z, Koed K, et al. DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature. 2005;434:864–870.
  • Nickoloff JA, Jones D, Lee SH, et al. Drugging the cancers addicted to DNA repair. J Natl Cancer Inst. 2017;109:1–13.
  • Karanam K, Kafri R, Loewer A, et al. Quantitative live cell imaging reveals a gradual shift between DNA repair mechanisms and a maximal use of HR in mid S phase. Mol Cell. 2012;47:320–329.
  • Toma M, Skorski T, Sliwinski T. DNA double strand break repair - related synthetic lethality. Curr Med Chem. 2018, in press.
  • Lord CJ, Tutt AN, Ashworth A. Synthetic lethality and cancer therapy: lessons learned from the development of PARP inhibitors. Annu Rev Med. 2015;66:455–470.
  • Nieborowska-Skorska M, Sullivan K, Dasgupta Y, et al. Gene expression and mutation-guided synthetic lethality eradicates proliferating and quiescent leukemia cells. J Clin Invest. 2017;127:2392–2406.
  • Lord CJ, Ashworth A. Mechanisms of resistance to therapies targeting BRCA-mutant cancers. Nat Med. 2013;19:1381–1388.
  • Murai J, Huang SY, Das BB, et al. Trapping of PARP1 and PARP2 by clinical PARP inhibitors. Cancer Res. 2012;72:5588–5599.
  • Bird AW, Yu DY, Pray-Grant MG, et al. Acetylation of histone H4 by Esa1 is required for DNA double-strand break repair. Nature. 2002;419:411–415.
  • Thomas CJ, Kotova E, Andrake M, et al. Kinase-mediated changes in nucleosome conformation trigger chromatin decondensation via poly(ADP-ribosyl)ation. Mol Cell. 2014;53:831–842.
  • Thomas C, Ji Y, Lodhi N, et al. Non-NAD-Like poly(ADP-Ribose) polymerase-1 inhibitors effectively eliminate cancer in vivo. EBioMedicine. 2016;13:90–98.
  • Podszywalow-Bartnicka P, Wolczyk M, Kusio-Kobialka M, et al. Downregulation of BRCA1 protein in BCR-ABL1 leukemia cells depends on stress-triggered TIAR-mediated suppression of translation. Cell Cycle. 2014;13:3727–3741.
  • Dkhissi F, Aggoune D, Pontis J, et al. The downregulation of BAP1 expression by BCR-ABL reduces the stability of BRCA1 in chronic myeloid leukemia. Exp Hematol. 2015;43:775–780.
  • Hehlmann R, Lauseker M, Saußele S, et al. Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants. Leukemia. 2017;31:2398–2406.
  • Slinker BK. The statistics of synergism. J Mol Cell Cardiol. 1998;30:723–731.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.